Urinary incontinence (UI) is the subject of a forthcoming study from Decision Resources, Inc., that examines the commercial potential of emerging drugs to treat this condition in the seven major pharmaceutical markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan) over a 2000-2010 forecast period.
(Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION )
Significant side effects and problems associated with administration of and compliance with existing drug therapies largely explain why the UI pharmacological market has failed to reach its potential. However, the first major pharmacological breakthroughs in UI in two decades-tolterodine (Pharmacia's Detrol), recently launched in all major markets except Japan (where it is in Phase II development), and extended-release oxybutynin (Alza's Ditropan XL) in the United States and the United Kingdom-have enlivened commercial interest in the UI market, especially the market for overactive bladder therapies.
In Urinary Incontinence, we evaluate the significant unmet needs and drug- development opportunities associated with this condition. Late-stage research and development efforts are focused largely on members of existing drug classes, albeit agents offering superior convenience or specificity. For instance, Pfizer's darifenacin reportedly has a higher selectivity for M3 receptors, which are involved in bladder overactivity. Hence, darifenacin could reduce bladder contractions while having a lesser effect on other muscarinic receptor subtypes, thereby diminishing unwanted side effects. This compound could find the greatest success of all the emerging therapies for UI.
Physicians are intrigued by the possibilities of potassium-channel openers as UI therapies. These compounds hyperpolarize the smooth muscle membrane in the bladder, making it less excitable and less likely to contract involuntarily. With AstraZeneca's ZD-0947 in Phase II development in the United States and Europe, a potassium-channel opener could be available in these geographical regions by 2005. Another promising therapy is the neuronal desensitizing agent resiniferatoxin (Afferon's RTX).
Urinary Incontinence offers invaluable market intelligence for pharmaceutical companies developing drugs to treat this indication. This study is part of Mosaic, one of six Pharmacor services available from Decision Resources that evaluate the commercial potential of drugs in research and development.
Decision Resources, Inc., is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Founded as a subsidiary of Arthur D. Little, Inc., the company has provided strategic information services for 30 years, assessing international pharmaceutical and health care industry trends. Visit Decision Resources at http://www.dresources.com/.
Contact Frank Sama, 781.296.2553 (tel), 781.296.2550 (fax), or email@example.com. In Europe, contact Francoise Bidart, +32.2.351.4082 (tel), +32.2.351.2347 (fax), or firstname.lastname@example.org. In Japan, contact Makiko Yoshimoto, +81.3.5401.2615 (tel), +81.3.5401.2617 (fax), or email@example.com.
AP Archive: http://photoarchive.ap.org/
PRN Photo Desk, 888-776-6555 or 201-369-3467
SOURCE: Decision Resources, Inc.
Contact: Frank Sama of Decision Resources, Inc., 781-296-2553,